Skip to content
Film Television Auditions – Lifestyle
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
April 9, 2026
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
April 9, 2026
Boehringer Ingelheim’s Athens Site Achieves Carbon Neutral Operations, Advancing 2030 Commitments
April 6, 2026
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
March 25, 2026
←
Previous Page
1
2
3